Dr. Heymach Discusses the CheckMate-026 Study in Lung Cancer

John V.Heymach, MD, PhD
Published: Friday, Apr 07, 2017



John V. Heymach, MD, PhD, chairman, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the CheckMate-026 trial in lung cancer.

This randomized study compared frontline nivolumab (Opdivo) with chemotherapy in patients with lung cancer that had PD-L1 positivity.

Although the trial was negative, tumor mutation burden was found to be a good predictor of who was likely to derive benefit from immunotherapy as opposed to chemotherapy, says Heymach.
 


John V. Heymach, MD, PhD, chairman, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the CheckMate-026 trial in lung cancer.

This randomized study compared frontline nivolumab (Opdivo) with chemotherapy in patients with lung cancer that had PD-L1 positivity.

Although the trial was negative, tumor mutation burden was found to be a good predictor of who was likely to derive benefit from immunotherapy as opposed to chemotherapy, says Heymach.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: ALK-Positive NSCLC: Emerging Strategies to Inform Sequencing, Optimize Outcomes, and Address Unmet Clinical Needs Along the Disease ContinuumAug 29, 20181.5
Community Practice Connections™: Oncogenic Tumor Board in Advanced NSCLC: Leveraging Actionable Mutations Along the Disease Continuum to Optimize Patient OutcomesAug 30, 20182.0
Publication Bottom Border
Border Publication
x